Auris Medical Holding AG (NASDAQ:EARS) dropped 7.2% on Tuesday . The stock traded as low as $3.81 and last traded at $3.84, with a volume of 73,836 shares changing hands. The stock had previously closed at $4.14.

EARS has been the subject of several research analyst reports. Leerink Swann reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research note on Thursday, May 12th. Jefferies Group reaffirmed a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Finally, Zacks Investment Research raised shares of Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a research note on Tuesday, July 12th.

The firm’s market capitalization is $138.35 million. The stock’s 50-day moving average price is $3.94 and its 200 day moving average price is $3.96.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.04. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, equities analysts anticipate that Auris Medical Holding AG will post ($1.01) EPS for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.